DEA Supports White House Plan To Streamline Research Of Psychedelics and Cannabis

While testifying at a recent House subcommittee hearing, the Drug Enforcement Administration (DEA) and National Institute On Drug Abuse (NIDA) signaled their willingness to align with a White House proposal that seeks to streamline the process of researching Schedule I drugs.

The federal government’s treatment of Schedule I drugs, which includes LSD, MDMA, cannabis and peyote, is defined by the DEA as having “no accepted medical use and a high potential for abuse” has prevented many beneficial drugs from being readily obtained and studied by researchers.

Studies are showing that cannabis and a variety of psychedelic drugs are proving effective for treating a range of mental injuries, for instance, clinical studies of MDMA-assisted therapy to treat PTSD, which is currently in Phase III trials with the FDA.

Marijuana Moment reported that the DEA has said in written testimony that “expanding access to Schedule I research is a critical part of the DEA’s mission to protect public safety and health.”

The proposal looks to align research limitations of Schedule I drugs with those of less-restricted Schedule II drugs, which include effective and widely prescribed drugs like hydrocodone, Adderall and Ritalin. Researchers and policymakers alike have pointed out that existing protocols for studying Schedule I substances have for decades restricted essential research of therapies that could save lives.

“It is critical that the scientific and medical community study Schedule I substances, as some may turn out to have therapeutic value,” DEA principal deputy administrator Louis Milione said. “DEA supports the administration’s legislative proposal’s expansion of access to Schedule I research. DEA looks forward to continuing to work with the research community and our interagency partners to facilitate Schedule I research.”

Current regulations include onerous situations where each researcher involved in a Schedule I drug study must obtain individual DEA registration. The proposal would make it possible for multiple researchers at a given institution to be authorized to participate under a single registration and potentially extend to multiple location sites as well.

Nora Volkow, director of NIDA, has voiced her opposition to the handling of Schedule I drugs and how such rules impede viable research. “One of the barriers that has actually been noted is that cannabis, by being a Schedule I substance, requires certain procedures that actually can be very lengthy,” Volkow said. “In some instances, it detracts researchers who want to investigate it because it’s just much more cumbersome than doing studies with other substances.” 

Posted In: Drug Enforcement AdministrationMDAM-assisted TherapyNational Institute on Drug AbuseWhite HouseCannabisGovernmentRegulationsMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.